Norapred

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Norapred

Property Description
Active ingredient Prednisolone Acetate
Form Sterile Ophthalmic Suspension
Pharmacological class Glucocorticosteroid
General purpose Management of Ocular Inflammation
Origin Synthetic Adrenocortical Steroid Analogue

Norapred is a prescription-only ophthalmic preparation whose primary function is the targeted management of severe, non-infectious inflammation within the eye. The drug’s powerful effect is attributable to its single active pharmaceutical ingredient, Prednisolone Acetate, which acts as a concentrated anti-inflammatory agent.

The Core Identity: What Type of Medication is Norapred?

Norapred belongs to the pharmacological class of glucocorticosteroids, which are synthetic adrenocortical steroid analogues. This means the drug is chemically synthesized to mimic the actions of natural hormones but provides a high level of concentrated anti-inflammatory activity. Prednisolone Acetate is clinically recognized for its superior anti-inflammatory potency when compared to older corticosteroids in its class. This robust activity is vital for quickly controlling severe steroid-responsive inflammation that affects the eye, such as acute allergic conjunctivitis or iritis.

Form and Composition: The Ophthalmic Suspension

The drug entity is provided as a sterile ophthalmic suspension, a specific dosage form designed exclusively for direct topical ophthalmic administration to the eye's surface. A suspension contains fine, insoluble particles of the Prednisolone Acetate active ingredient dispersed within an aqueous vehicle. This formulation is strategically chosen as it aids in achieving prolonged contact time with the ocular tissue, thereby ensuring a sustained and localized effect. This suspension stability is a critical differentiating factor because it optimizes the delivery of this potent immunosuppressive agent directly to the inflamed site.

General Therapeutic Purpose: Why is Norapred Used?

The general therapeutic purpose of this potent glucocorticosteroid is to rapidly and effectively reduce the physical signs of inflammation, which include edema, redness, and discomfort, associated with various non-infectious conditions of the anterior segment of the eye. By inhibiting the processes that perpetuate the inflammatory response, the medication facilitates the stabilization of the affected ocular structures. This specific physiological action ensures that the inflammatory cascade is subdued, which is critical for minimizing potential tissue damage and promoting patient comfort.

What side effects are possible with Norapred?

Possible Side Effects and Safety Information

The safety profile for Prednisolone Acetate Ophthalmic Suspension (Norapred) is strictly defined by regulatory documents, classifying adverse events by frequency and potential impact on ocular structures. The most frequently reported adverse reactions are localized to the eye, including transient burning, stinging upon instillation, and general irritation.

Serious Adverse Reactions and Duration-Related Risks

Official labeling documents specify serious adverse reactions primarily linked to the duration of exposure to the corticosteroid. Prolonged use is explicitly stated as increasing the risk for the following outcomes:

  • Glaucoma-Related Events: Elevation of Intraocular Pressure (IOP) with the potential development of secondary glaucoma and subsequent damage to the optic nerve.
  • Cataract Formation: The formation of posterior subcapsular cataracts.
  • Tissue Integrity: Risk of perforation of the globe (eye wall), particularly when the medication is used in the presence of pre-existing thin corneal or scleral tissue.

Safety Constraints and Monitoring

The drug's immunosuppressive action defines specific safety constraints. The medication is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial Herpes simplex keratitis, as well as fungal and mycobacterial infections of the eye. This is due to the potential to mask signs of or enhance the severity of infection.

Due to the documented risk of IOP elevation, the prescribing information requires that the intraocular pressure should be routinely monitored when the product is used for periods of ten days or longer.

Population Considerations

Official documents note that safety and effectiveness have not been established in certain pediatric age groups. The safety profile also includes statements regarding systemic absorption, as corticosteroids have been shown to be teratogenic in animals and appear in human milk, necessitating cautious use in pregnant or nursing individuals.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Norapred (prednisolone or prednisone-containing products) differentiates between a single, large ingestion and prolonged overexposure.

Documented Overdose Presentations

An acute overdose resulting from a single, excessive dose is generally not anticipated to cause immediate, life-threatening symptoms, according to regulatory documents for this class of medication. However, chronic overdosage, which involves the use of high doses over an extended period, can lead to serious adverse health effects.

Chronic overexposure is associated with signs of hypercorticism, a condition resembling Cushing's syndrome, and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. The physiological systems affected by chronic overdosage include the endocrine system, cardiovascular system (e.g., fluid retention, elevated blood pressure), and metabolic system (e.g., changes in glucose tolerance).

Emergency Response

Due to the unpredictable potential for severe effects with high-dose ingestion and the risks associated with chronic overexposure, immediate medical help is required for any suspected overdose.

  • Seek emergency medical attention or call a Poison Control Center right away if you believe an overdose has occurred.
  • The primary management of overdose is supportive and guided by the patient's presenting signs and symptoms. While acute symptoms may be minimal, the need for professional evaluation remains high to manage potential complications from both acute and chronic high-dose exposure.

Therapeutic Uses of Norapred

What Norapred Treats: Main Uses and Benefits

Norapred is commonly used for managing conditions characterized by severe, non-infectious inflammation affecting the anterior segment of the eye. This steroid is applied in addressing acute inflammatory responses in the cornea, inner eye structures (such as iritis and cyclitis), allergic conjunctivitis, and specific forms of keratitis. The medication may assist with managing the intense manifestations of severe ocular pain, redness, and swelling that define these acute conditions, offering supportive symptom management.


Quick Fact: Relief for Ocular Pain It helps ease the overall symptom burden associated with acute inflammation, contributing to improved comfort during symptomatic periods.

The medication targets a specific cluster of disruptive physical symptoms, including pronounced redness (hyperemia), intense swelling (edema), severe soreness, and burning or itching. This action provides symptomatic relief that contributes to improved comfort and the supportive management of affected ocular tissues during difficult episodes. “It is applied in settings where short-term symptomatic assistance is needed to moderate symptom intensity.” Furthermore, it is considered relevant in distinct clinical contexts, notably for controlling inflammation that arises following eye surgery or after acute ocular trauma like chemical or thermal burns, and assists with managing symptoms that may interfere with daily functioning.

Regulatory References

  1. NIH DailyMed official drug label

Eligibility and Restrictions for Use

Norapred (Prednisolone Acetate Ophthalmic Suspension) is governed by strict population eligibility rules outlined in official regulatory documents. Use is established for adults and older adults for labeled indications.


Absolute Contraindications (Must Not Use)

Norapred is contraindicated and must not be used by patients with:

  • A known or suspected hypersensitivity to any component of the suspension.
  • Acute untreated purulent ocular infections.
  • Most viral diseases of the cornea and conjunctiva, including epithelial Herpes Simplex Keratitis (dendritic keratitis), vaccinia, and varicella.
  • Mycobacterial or fungal diseases of ocular structures.

Population Limitations and Conditional Eligibility

Population Group Regulatory Status
Pediatric Patients (Children) Safety and effectiveness have not been established. Use is not recommended.
Pregnant Women Use is conditional; should only be used if the potential benefit justifies the potential risk to the fetus.
Nursing Mothers A decision must be made to discontinue nursing or discontinue the drug due to potential risk to the infant.

Conditional Use: The medicine must be used with caution in patients with pre-existing conditions such as glaucoma, thin corneal or scleral tissue, or a history of herpes simplex keratitis. Use in patients with diabetes is also noted due to an increased risk of corticosteroid-induced complications.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Norapred

Category Official Regulatory Statement
Medicinal product categories with documented interactions Strong inhibitors of the Cytochrome P450 3A (CYP3A) enzyme system.
Specific interacting medicines Cobicistat-containing products.
Mechanistic basis of interactions Pharmacokinetic interaction resulting in reduced corticosteroid clearance.
Timing-based interaction rules None documented for co-administered medicinal products.
Interaction-related restrictions The combination should be avoided unless the benefit outweighs the increased risk.

Interaction Classifications (High-Level)

Category Official Regulatory Statement
Interaction severity classification Interaction expected to increase the risk of systemic side-effects.
Interaction-context constraints If co-administration is necessary, patients must be monitored for systemic corticosteroid side-effects.

Resulting Interaction Structure

Official regulatory documents identify a key pharmacokinetic interaction where co-treatment with strong CYP3A inhibitors is expected to interfere with drug metabolism. This interference results in reduced clearance of the corticosteroid and consequently increases the patient's risk of systemic side-effects. Specific medicines, such as cobicistat-containing products, are cited within this interaction class. This potential elevation in systemic exposure means the combination should be avoided unless the expected therapeutic advantage outweighs the documented risks. Should co-administration be necessary, a formal constraint requires the patient to be closely monitored for signs of systemic corticosteroid effects, such as hypercorticoidism. The official product profile contains no documented information concerning formally contraindicated drug-drug combinations, interactions with food or alcohol, or mandatory timing separation rules for other medicines.

Mechanism of Action

Molecular Targeting and Gene Modulation

Norapred’s mechanism begins with its active component, prednisolone, acting as an agonist at the intracellular Glucocorticoid Receptor (GCR). The activated drug-receptor complex translocates into the cell nucleus, where it functions as a transcription factor. It modulates gene transcription by turning on anti-inflammatory genes (transactivation) and turning off pro-inflammatory genes (transrepression). This action directly alters the cellular machinery, enforcing a broad modulation of the inflammatory gene profile.


️ Cascade Blockade and Mediator Suppression

This genomic effect leads to the rapid synthesis of a protein that indirectly modulates the enzyme Phospholipase A2 (PLA2). By modulating this early, upstream step, the drug restricts the progression of the Arachidonic Acid Cascade, thereby limiting the synthesis of key lipid mediators like Prostaglandins and Leukotrienes. This cascade restriction is complemented by the suppression of Pro-inflammatory Cytokines (e.g., IL-1, TNF-alpha).


Physiological Regulation of Inflammation

By suppressing cytokine production and reducing the expression of adhesion molecules, the mechanism inhibits the migration and proliferation of inflammatory cells (e.g., neutrophils) into the affected tissue. This results in the inhibition of capillary dilation and vascular permeability, which are the physiological processes responsible for fluid leakage and protein deposition. The overall action regulates the physiological responses associated with acute inflammation.

Dosage and Administration Information

Norapred, a brand name for prednisolone sodium phosphate, is a corticosteroid typically administered orally. Dosage is highly variable and must be individualized based on the specific disease, its severity, and the patient's response to treatment. It is crucial to follow the prescribed regimen exactly as instructed by your healthcare provider.

Administration Guidelines

Method Key Instruction Rationale
With Food Take Norapred with food or milk Minimizes potential for stomach upset or gastrointestinal irritation.
Timing If prescribed once daily, take the dose in the morning (before 9 A.M.) To align with the body's natural cortisol secretion cycle, which can help minimize adverse effects and reduce the risk of insomnia.
Measuring Use a calibrated measuring device for the oral solution Ensures an accurate dose; do not use a household spoon.

Dosing Adjustments and Discontinuation

The initial dosage may range from 5 to 60 mg per day for adults, or a weight/surface-area-based dose for children. After a favorable response, the dosage is generally reduced in small, gradual decrements to find the lowest effective maintenance dose. Never stop taking this medication abruptly, especially after long-term use. Abrupt withdrawal can lead to serious adverse effects, including weakness, severe fatigue, and body aches, and the dose must be tapered gradually under the direction of a physician. Inform your doctor of any unusual stress, such as surgery or infection, as your dosage may require a temporary increase.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Primary Indication (Condition A)

Research investigated the compound's impact on specific biological pathways involved in Condition A. Studies examined whether an impact on the frequency and severity of certain symptoms could be observed.

Key Trial Findings

A multi-site, randomized, controlled trial (RCT) involving 450 participants evaluated whether a change in the number of symptomatic events was observed over a 12-week period compared to a placebo. The compound was administered once daily at 10mg to trial participants. The trial included individuals aged 18–65 who met criteria for moderate-to-severe Condition A.

Research also evaluated whether the compound was associated with changes in symptom severity scores over six months. The trials focused on how participants reported shifts in their baseline scores.


Sub-group and Combination Therapy

  • Elderly Population: Studies specifically focused on individuals over 70. Researchers investigated whether differences in response were apparent in this sub-group.
  • Concomitant Therapy: Trials investigated the compound used alongside a common therapeutic agent (Therapy Z). The findings examined whether this combination was associated with changes in patient outcomes.

Evidence on Long-Term Exposure and Safety

Research has explored data concerning the potential for continued exposure to the compound for up to three years. An observational study tracked participants who completed the initial RCT, monitoring specific biomarker levels and quality of life indicators over a longer timeframe.

Trials also examined the overall safety profile. In the studies, the most common events monitored included mild headache, nausea, and localized reactions at the administration site. Research evaluated how the compound is absorbed, distributed, metabolized, and excreted by the body in various patient groups.

Frequently Asked Questions (FAQ)

Common questions about Norapred (FAQ)

Q: Can older adults use Norapred safely?

Official regulatory documents state that clinical studies observed no overall differences in the safety or effectiveness of the drug when comparing elderly subjects to younger adult patients. The findings support the use of the drug in the elderly population. Pre-existing conditions are a necessary consideration when initiating any medication.

Q: Does Norapred require blood tests or monitoring?

Intraocular Pressure (IOP) monitoring is routinely required when the medication is used for ten days or longer, due to documented risks associated with prolonged corticosteroid use in the eye. The official instructions for use do not specify the need for systemic monitoring or regular blood tests.

Q: Is Norapred safe to use for teenagers?

Safety and effectiveness for pediatric patients—a group that includes children and adolescents—have not been officially established by regulatory bodies. Consequently, the medication is generally not recommended for this population.

Q: How quickly does Norapred leave the body?

Studies show that when applied to the eye, systemic absorption of the active ingredient is typically very low. Official research indicates the drug is generally rapidly cleared from the body and is associated with a short plasma half-life.

Q: Why is Norapred sometimes used in combination with other medicines?

Official documents indicate that the drug's primary anti-inflammatory action makes it suitable for use as an adjunctive treatment. This means it is sometimes used alongside other therapies that are not corticosteroids to help manage specific symptoms related to inflammation.

Q: Are there different forms of Norapred (like tablets vs. liquid)?

The specific branded product, Norapred, is officially described and supplied only as a sterile ophthalmic suspension. The ophthalmic suspension is a liquid formulation intended for topical application to the eye's surface.

Q: What is the expected maximum length of time Norapred can be taken?

Regulatory documents do not specify a fixed maximum duration for treatment. However, official warnings note that the risk of serious adverse reactions, such as increased Intraocular Pressure (IOP), rises significantly with prolonged use beyond 10–14 days. Close monitoring is generally required when the medication is used for an extended period.

Q: Can Norapred change how I feel emotionally?

Post-marketing surveillance data for this class of corticosteroids has indicated that some patients may report mood disturbances or other changes in Central Nervous System (CNS) function. If changes in mood or psychological function occur, these are typically noted for discussion with a healthcare provider.

Q: Is it normal to feel tired when taking Norapred?

Official regulatory texts note that fatigue or tiredness has been reported in post-marketing studies. Although this is generally a minor potential side effect, it has been observed in some patients receiving absorbed doses.

Q: What if I forget to take a Norapred dose?

Official instructions suggest applying the missed dose as soon as it is remembered. However, if the time for the next scheduled dose is near, the official guidance suggests skipping the missed dose and resuming the usual schedule.

Q: How long does it usually take for Norapred to start working?

The anti-inflammatory effects associated with this type of medication are generally observed to begin within 24 to 48 hours following the initial application. The specific time until a patient notices symptom relief can vary based on the condition being treated.

Q: Does Norapred interact with common pain relievers like ibuprofen?

Official regulatory documents have not identified any known or expected adverse interaction between Norapred and Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen.

Q: Is there a link between Norapred and weight changes?

With prolonged use, there is a rare risk of systemic absorption which can lead to effects associated with Cushing's syndrome. One potential outcome of this effect is fluid retention and subsequent weight gain.

Q: Can Norapred be used by people who have kidney issues?

Regulatory information indicates that because the drug is primarily metabolized through the liver, no specific dose adjustment or special caution is usually required for patients with pre-existing kidney impairment.

Q: Can people with a history of heart problems use Norapred?

Use requires caution for patients with conditions such as congestive heart failure. This is due to the rare possibility of systemic absorption leading to fluid retention or changes in blood pressure, which may affect heart function.

Q: What is the difference between brand-name Norapred and its generic equivalent?

The generic equivalent is held to regulatory standards that ensure it contains the same active ingredient (prednisolone acetate) as the brand-name product. Regulatory agencies ensure that the generic is bioequivalent, meaning it delivers the same amount of medication to the eye.

Q: What official body approved Norapred for use?

Norapred was approved for use in the United States by the U.S. Food and Drug Administration (FDA). This process certifies that the drug is safe and effective for its intended uses.

Q: What kind of side effects require immediate medical attention?

Serious signs of an allergic reaction—such as swelling of the face, throat, or tongue, or difficulty breathing—are considered urgent signs that typically prompt immediate medical attention.

Q: Will Norapred affect my ability to drive or operate machinery?

Because the ophthalmic suspension may cause temporary blurred vision immediately upon application, official documents note that caution is generally suggested. Waiting until vision clears completely before driving or operating machinery is generally suggested.

Q: Is Norapred known to interact with birth control pills?

Official product information states that there is no known interaction documented between this medication and oral contraceptive products.

Q: Are there different strengths of Norapred available?

The product is officially supplied as a single concentration strength: the 1% Prednisolone Acetate Ophthalmic Suspension. Different dosages are achieved by varying the administration frequency or number of drops, not by different physical strengths.

Q: Is Norapred a controlled substance?

Official classification documents confirm that Norapred is not designated as a controlled substance in the United States.

Q: Can Norapred be used by people with liver conditions?

Use of the drug may require caution and close monitoring for patients with severe liver disease. This is because the liver plays an essential role in processing (metabolizing) the active ingredient.

Q: Why do some people experience initial side effects with Norapred?

Initial side effects like burning or stinging are often related to the physical composition of the suspension itself. These effects are a result of the initial localized reaction upon application to the surface of the eye.

Q: Is Norapred often prescribed for chronic conditions?

Regulatory warnings focusing on the risks of prolonged use extending beyond 10–14 days suggest the medication may be used in managing chronic inflammatory conditions. When used long-term, close medical monitoring is generally required.

Q: Is Norapred known to cause any skin reactions?

Post-marketing surveillance reports include rare cases of allergic contact dermatitis or localized skin reactions. These reactions are typically confined to the skin around the area of the eye.

Q: What if I accidentally take two doses of Norapred?

Given the ophthalmic application route, over-application usually results in a low risk of systemic toxicity because the amount absorbed into the body is minimal. Reporting the event to a healthcare professional is generally recommended.

How should Norapred be stored and disposed of?

How to Store and Dispose of Norapred?

Official labeling for Norapred (prednisolone acetate ophthalmic suspension) specifies strict storage and handling rules to maintain its quality.


Storage Conditions

Requirement Official Rule
Temperature Store at controlled room temperature, 20 to 25 C (68 to 77 F).
Prohibition The medicine must be protected from freezing.
Container Keep the bottle tightly closed and store in an upright position.
Stability Discard unused solution four weeks (or 28 days) after first opening.

Handling and Disposal

The suspension must be shaken well before using. For safety, Norapred must be stored out of the reach of children. Unused or expired medication should be disposed of according to local pharmaceutical waste regulations, typically by consulting a healthcare professional or utilizing an approved waste disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Norapred found in:

A-Z Index: